Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531469 | 0.86 | MEN1 (0.43) | KMT2AMEN1ALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL6744834 | 0.85 | KMT2A (0.56) | KMT2AMEN1ALDH1A1NPSR1MAPT | |
| SCHEMBL7614697 | 0.83 | PPARG (0.41) | KMT2AMEN1ALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL7618868 | 0.82 | ACHE (0.42) | KMT2AMEN1ALDH1A1L3MBTL1CNR2 | |
| SCHEMBL6743658 | 0.81 | KMT2A (0.53) | KMT2AMEN1ALDH1A1NPSR1MAPT | |
| SCHEMBL963777 | 0.81 | MEN1 (0.52) | KMT2AMEN1ALDH1A1L3MBTL1HPGD | |
| SCHEMBL9689759 | 0.78 | MEN1 (0.70) | KMT2AMEN1ALDH1A1NPSR1MAPT | |
| SCHEMBL6744201 | 0.77 | KMT2A (0.69) | KMT2AMEN1ALDH1A1NPSR1MAPT | |
| SCHEMBL7529497 | 0.76 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1L3MBTL1CNR2 | |
| SCHEMBL27555232 | 0.76 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1L3MBTL1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696573-B1 | SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1209150-A1 | PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ADH1A, ADH1C, OXER1 | KMT2A 938/4885MEN1 3399/4885ALDH1A1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.